Recently Completed Clinical Trials
The following trials were recently completed. When results are reported, they may provide helpful information for doctors treating mesothelioma patients.
Erlotinib in Treating Patients with Malignant Mesothelioma of the Lung
Condition: Mesothelioma
Decitabine in Treating Patients with Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura
Conditions: Mesothelioma, Esophageal Cancer, Lung Cancer, Metastatic Cancer
PXD101 as Second-Line Therapy in Treating Patients with Malignant Mesothelioma of the Chest that Cannot Be Removed by Surgery
Condition: Mesothelioma
EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer
Conditions: Mesothelioma, Peritoneal Cavity Cancer, Metastatic Cancer Cancer
Combination Chemotherapy and Tamoxifen in Treating Patients with Solid Tumors
Conditions: Mesothelioma, Adrenocortical Carcinoma, Head and Neck Cancer, Brain and Central Nervous System Tumors, Liver Cancer, Sarcoma, Pheochromocytoma
Inhaled Doxorubicin in Treating Patients with Advanced Solid Tumors Affecting the Lungs Conditions: Mesothelioma, Lung Cancer, Thymoma and Thymic Carcinoma, Metastatic Cancer
Vaccine Therapy and GM-CSF in Treating Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma
Conditions: Leukemia, Lung Cancer, Mesothelioma, Peritoneal Cavity Cancer, Myelodysplastic Syndromes
Immunotoxin Therapy in Treating Patients with Advanced Cancer
Conditions: Cervical, Ovarian or Fallopian Tube Cancer, Head and Neck Cancer, Mesothelioma, Lung Cancer, Pancreatic Cancer, Peritoneal Cavity Cancer
Immunotoxin Therapy in Treating Patients with Advanced Solid Tumors
Conditions: Cervical, Ovarian and Fallopian Tube Cancer, Head and Neck Cancer, Mesothelioma, Lung Cancer, Pancreatic Cancer, Peritoneal Cavity Cancer
PV701 in Treating Patients with Advanced or Recurrent Peritoneal Cancer
Condition: Cancer
MS-275 in Treating Patients with Advanced Solid Tumors or Lymphoma
Condition: Cancer
ALIMTA (Pemetrexed) Alone or in Combination with Cisplatin for Patients with Malignant Mesothelioma.
Condition: Mesothelioma
Following the completion of this study, Alimta® was approved for marketing.